The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma-Reference-Cited by-同舟云学术

The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma

Published:2023-01 Issue:1 Volume:83 Page:10-14
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Bedke Jens,Albiges Laurence,Capitanio Umberto,Giles Rachel H.,Hora Milan,Ljungberg Börje,Marconi Lorenzo,Klatte Tobias,Volpe Alessandro,Abu-Ghanem Yasmin,Dabestani Saeed,Fernández-Pello Sergio,Hofmann Fabian,Kuusk Teele,Tahbaz Rana,Powles Thomas,Bex Axel

Publisher

Elsevier BV

Subject

Urology

Reference11 articles.

1. 2021 Updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma;Bedke;Eur Urol,2022

2. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma;Choueiri;N Engl J Med,2021

3. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;Powles;Lancet Oncol,2022

4. LBA67 – Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial;Allaf;Ann Oncol,2022

5. LBA4 – Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase III CheckMate 914 trial;Motzer;Ann Oncol,2022

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

2. Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy;Medical Oncology;2024-09-05

3. NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10;Cell Communication and Signaling;2024-09-03

4. EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After Surgery;European Urology;2024-09

5. Frequent gene mutations and the correlations with clinicopathological features in clear cell renal cell carcinoma: preliminary study based on Chinese population and TCGA database;BMC Urology;2024-08-09